Industry News

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

By Labmedica International staff writers
21 Jan 2022

Illustration

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application of immunofluorescence assays in clinical diagnostics and research, and growing investments and expenditure in healthcare sector.


These are the latest findings of Reports and Data (New York City, NY, USA), a market research and consulting company.


IFA is a microscopic technique primarily used on microbiological samples, which uses the specificity of antibodies to their antigens. Antibodies are labeled with fluorescent dye and the subsequently formed antigen-antibody complex can be visualized using fluorescent microscope. Immunofluorescence assays are of two types: direct immunofluorescence, which uses primary antibody that is conjugated to fluorescent dye and indirect immunofluorescence in which a secondary antibody is conjugated with fluorophore against a primary antibody that is used for detection. IFA is a standardized technique extensively used in virology to determine the presence of antibodies by their specificity to viral antigens that are expressed by the infected cells. IFAs have also been used to develop antibodies against SARS-CoV-2 to enable efficient detection and curb the spread of the virus, and this trend is expected to continue going forward.


The development of advanced medical facilities, increasing biopharmaceutical R&D, rising focus on antibody-based therapies, and increasing number of preclinical and clinical research studies globally are some of the key factors expected to drive market growth. However, the lack of skilled professionals and techniques and high costs of assays are expected to hamper market growth to a certain extent.


Based on product, the kits segment is expected to account for the largest revenue share in the global IFA market owing to increasing demand for complete solutions, calibrated reagents and controls from pharmaceutical and biotechnology companies, and CROs. Based on type, the indirect immunofluorescence segment is expected to register the fastest revenue growth due to numerous advantages offered by the technique such as improved flexibility, sensitivity, improved signal amplification and higher cost-effectiveness as compared to direct immunofluorescence.


Based on disease, the cancer segment is expected to register significant revenue growth due to the high prevalence of cancer worldwide, growing healthcare burden, and increasing adoption of IFAs in screening and diagnosis of cancer. Based on end-use industry, the pharmaceutical and biotechnology companies segment is expected to account for a robust revenue share in the global IFA market owing to the increasing use of IFAs in antibodies-based therapeutics research and drug discovery and development processes.


Geographically, North America is expected to account for the largest revenue share of the global IFA market due to the increasing healthcare burden of chronic and infectious diseases, advancements in drug discovery and research, rising funding by government and other organizations, and availability of favorable reimbursement policies in the region.


Related Links:
Reports and Data



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

20 May 2022
Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business
QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.
Read More
16 May 2022
Medtronic Completes Acquisition of Intersect ENT to Add Innovative Sinus Implants to ENT Portfolio
Medtronic plc (Dublin, Ireland) has completed the acquisition of Intersect ENT (Menlo Park, CA, USA), thereby expanding the company's comprehensive ear, nose, and throat (ENT) portfolio with innovative products used in sinus procedures to improve post-operative outcomes and to treat nasal polyps.
Read More
12 May 2022
Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications
The global lateral flow assays market is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing prevalence of influenza, STDs, and tuberculosis worldwide and rising awareness among people about the availability of POCT kits.
Read More
11 May 2022
Global Rapid Test Kits Market Driven by Immunoassay and Chromatography-Based Tests
The global rapid test kits market size was valued at more than USD 25.50 billion in 2021 and is expected to register a CAGR of 8.1% over the 2019-2030 period to surpass USD 52 billion in 2030, driven primarily by the increasing prevalence of various infectious diseases.
Read More
03 May 2022
Meridian Acquires Euprotein to Further Expand Recombinant Protein Capabilities
Meridian Bioscience, Inc. (Cincinnati, OH, USA) has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc. (North Brunswick Township, NJ, USA).
Read More
02 May 2022
Globe Scientific Acquired by L Squared Capital Partners
Globe Scientific (Mahwah, NJ, USA), a provider of laboratory consumable supplies, has been acquired by L Squared Capital Partners (Newport Beach, CA, USA), marking its third acquisition as part of GSI Group Holdings.
Read More
29 Apr 2022
GE Healthcare and Medtronic Collaborate to Improve Product Access for ASCs and OBLs
GE Healthcare (Chicago, IL, USA) and Medtronic (Doral, FL, USA) have entered into a collaboration focused on the unique needs and demand for care at Ambulatory Surgery Centers (ASCs) and Office Based Labs (OBLs) that will allow customers to access extensive product portfolios, financial solutions, and exceptional service.
Read More
22 Apr 2022
Global Diagnostic Imaging Market to Surpass USD 33 Billion by 2026
The global diagnostic imaging market is projected to grow at a CAGR of 4.9% from an estimated USD 27.5 billion in 2022 to over USD 33 billion by 2026, driven by technological advancements, favorable demographic factors in the developed regions, growing access to healthcare and rising income levels of the middle class population in the developing regions.
Read More
22 Apr 2022
Global Electrosurgery Market to Reach Almost USD 6 Billion by 2026
The global electrosurgery market is projected to grow at a CAGR of 3.6% from an estimated USD 5 billion in 2022 to almost USD 6 billion by 2026, driven by the rapidly rising number of surgeries being performed globally, an aging population, and increasing prevalence of various chronic diseases.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions